Matthew Plunkett

Matthew Plunkett has extensive experience in executive leadership roles within the biotechnology and pharmaceutical industry. Matthew currently serves as the Chief Financial Officer at Aeovian Pharmaceuticals, a position they have held since March 2022. Prior to this, they were the Chief Financial Officer at Imago BioSciences, Inc. from January 2021 to September 2021.

From 2018 to 2020, Plunkett served as the SVP & Chief Financial Officer at Nkarta Therapeutics, Inc., a development-stage cell therapy company. During their tenure, they were involved in a $114 million Series B financing and was responsible for financing, financial operations, communications, and buy-side and sell-side relationships.

Plunkett also held the role of Chief Financial & Business Officer at Medeor Therapeutics from September 2017 to November 2018, where they led a $57 million Series B financing and focused on buy-side and sell-side relationships, IPO readiness, regulatory and development strategy, and manufacturing relationships.

Before that, they served as the EVP, Chief Business Officer at CTI BioPharma from September 2012 to August 2017, where they were responsible for corporate strategy, pharma partnerships, asset acquisitions, and financing. Matthew also held the position of Chief Financial Officer at the California Institute for Regenerative Medicine from November 2011 to August 2012, where they revamped financial reporting systems and managed a challenging IT project.

Plunkett's earlier experience includes the role of VP & Chief Financial Officer at iPierian, a venture-backed private company focused on drug discovery using stem cell technologies, from August 2009 to April 2011. Additionally, they worked as a Managing Director and Head of West Coast Biotechnology at Oppenheimer & Co., as well as an Executive Director at CIBC World Markets.

Plunkett began their career as a Staff Scientist at Sunesis Pharmaceuticals from May 1998 to November 2000. Throughout their work experience, Plunkett has consistently shown expertise in financing, financial operations, corporate strategy, and building strong relationships within the biotech and pharmaceutical industry.

Matthew Plunkett attended St. Thomas Academy from 1982 to 1988, where they completed their high school education. Matthew then enrolled at Harvey Mudd College from 1988 to 1992, earning a Bachelor of Science degree in Chemistry. Following this, they pursued further education and obtained a PhD in Chemistry from the University of California, Berkeley, completing the program from 1992 to 1996. In 2015, they also participated in The Berkeley Executive Leadership Program at the Haas School of Business, University of California, Berkeley.